BR112022019628A2 - Composto da fórmula (i), enantiômero único, composição farmacêutica, processo para a preparação desta, método para o tratamento de uma condição ou distúrbio mediado pela atividade antagonista do receptor de trpv4 em um animal incluindo um humano, uso de um composto e composto representado pela fórmula (i-d) - Google Patents

Composto da fórmula (i), enantiômero único, composição farmacêutica, processo para a preparação desta, método para o tratamento de uma condição ou distúrbio mediado pela atividade antagonista do receptor de trpv4 em um animal incluindo um humano, uso de um composto e composto representado pela fórmula (i-d)

Info

Publication number
BR112022019628A2
BR112022019628A2 BR112022019628A BR112022019628A BR112022019628A2 BR 112022019628 A2 BR112022019628 A2 BR 112022019628A2 BR 112022019628 A BR112022019628 A BR 112022019628A BR 112022019628 A BR112022019628 A BR 112022019628A BR 112022019628 A2 BR112022019628 A2 BR 112022019628A2
Authority
BR
Brazil
Prior art keywords
compound
formula
treatment
preparing
human
Prior art date
Application number
BR112022019628A
Other languages
English (en)
Inventor
Shishido Yuji
Inoue Tadashi
Yamagishi Tatsuya
Ando Kazuo
Fukumoto Yutaka
Magara Ryohei
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of BR112022019628A2 publication Critical patent/BR112022019628A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTO DA FÓRMULA (I), ENANTIÔMERO ÚNICO, COMPOSIÇÃO FARMACÊUTICA, PROCESSO PARA A PREPARAÇÃO DESTA, MÉTODO PARA O TRATAMENTO DE UMA CONDIÇÃO OU DISTÚRBIO MEDIADO PELA ATIVIDADE ANTAGONISTA DO RECEPTOR DE TRPV4 EM UM ANIMAL INCLUINDO UM HUMANO, USO DE UM COMPOSTO E COMPOSTO REPRESENTADO PELA FÓRMULA (I-D). Esta invenção se refere a derivados de pirimidin-4(3H)-ona que atuam como moduladores do receptor TRPV4. A presente invenção também se refere a processos para a preparação de novos derivados de pirimidin-4(3H)-ona e ao seu uso no tratamento de uma ampla gama de doenças, síndromes e distúrbios, em particular para o tratamento de doenças ou distúrbios inflamatórios, dolorosos e urológicos.
BR112022019628A 2020-04-30 2021-04-30 Composto da fórmula (i), enantiômero único, composição farmacêutica, processo para a preparação desta, método para o tratamento de uma condição ou distúrbio mediado pela atividade antagonista do receptor de trpv4 em um animal incluindo um humano, uso de um composto e composto representado pela fórmula (i-d) BR112022019628A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017891P 2020-04-30 2020-04-30
PCT/JP2021/017277 WO2021221169A1 (en) 2020-04-30 2021-04-30 Pyrimidin-4(3h)-one derivatives as trpv4 antagonists

Publications (1)

Publication Number Publication Date
BR112022019628A2 true BR112022019628A2 (pt) 2022-11-16

Family

ID=78332043

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019628A BR112022019628A2 (pt) 2020-04-30 2021-04-30 Composto da fórmula (i), enantiômero único, composição farmacêutica, processo para a preparação desta, método para o tratamento de uma condição ou distúrbio mediado pela atividade antagonista do receptor de trpv4 em um animal incluindo um humano, uso de um composto e composto representado pela fórmula (i-d)

Country Status (10)

Country Link
US (1) US20230339934A1 (pt)
EP (1) EP4142874A4 (pt)
JP (1) JP2023523469A (pt)
KR (1) KR20230005227A (pt)
CN (1) CN115427409A (pt)
BR (1) BR112022019628A2 (pt)
CA (1) CA3180132A1 (pt)
MX (1) MX2022013607A (pt)
TW (1) TW202206430A (pt)
WO (1) WO2021221169A1 (pt)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2139896A1 (en) * 2007-03-23 2010-01-06 Pfizer Limited Pyrimido [4, 5-d]azepine derivatives as 5-ht2c agonists
JP5819397B2 (ja) 2010-03-23 2015-11-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Ｔｒｐｖ４拮抗薬
WO2011119704A1 (en) * 2010-03-23 2011-09-29 Glaxosmithkline Llc Trpv4 antagonists
JO3154B1 (ar) 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4
ES2571409T3 (es) 2011-06-17 2016-05-25 Glaxosmithkline Intellectual Property (No 2) Ltd Antagonistas espiro-cíclicos de TRPV4
ES2595606T3 (es) 2011-06-17 2017-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Antagonistas TRPV4
WO2013146754A1 (ja) 2012-03-27 2013-10-03 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
WO2015046193A1 (ja) * 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
US11260049B2 (en) 2016-09-20 2022-03-01 Glaxosmithkline Intellectual Property (No. 2) Limited TRPV4 antagonists
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
JP7195067B2 (ja) 2018-06-20 2022-12-23 花王株式会社 ロズマリン酸誘導体又はその塩

Also Published As

Publication number Publication date
CA3180132A1 (en) 2021-10-30
MX2022013607A (es) 2022-11-16
KR20230005227A (ko) 2023-01-09
EP4142874A4 (en) 2024-05-22
WO2021221169A1 (en) 2021-11-04
US20230339934A1 (en) 2023-10-26
EP4142874A1 (en) 2023-03-08
TW202206430A (zh) 2022-02-16
JP2023523469A (ja) 2023-06-05
CN115427409A (zh) 2022-12-02

Similar Documents

Publication Publication Date Title
Dal-Cim et al. Guanosine protects human neuroblastoma SH-SY5Y cells against mitochondrial oxidative stress by inducing heme oxigenase-1 via PI3K/Akt/GSK-3β pathway
Su et al. Rapamycin is neuroprotective in a rat chronic hypertensive glaucoma model
Sun et al. Maggot debridement therapy promotes diabetic foot wound healing by up-regulating endothelial cell activity
PT1165085E (pt) Derivados de ftalazina para tratar doencas inflamatorias
Moretti et al. TNF-α-induced depressive-like phenotype and p38MAPK activation are abolished by ascorbic acid treatment
Zhao et al. Hydroxytyrosol alleviates oxidative stress and neuroinflammation and enhances hippocampal neurotrophic signaling to improve stress-induced depressive behaviors in mice
BRPI0507050A (pt) composto, composição farmacêutica, e, métodos para a fabricação de um medicamento para antagonizar o efeito da substáncia p em seu sìtio receptor, ou para o bloqueio dos receptores da neurocinina-1 e para a fabricação de um medicamento para o tratamento de um distúrbio fisiológico associado com um excesso de taquicininas em um mamìfero
BR112022015572A2 (pt) Anticorpo, composição, composição farmacêutica, anticorpo para uso como um medicamento, métodos para tratar uma doença e para produzir um anticorpo, ácido nucléico, um ou mais ácidos nucléicos, célula, e, kit de partes
BR112021026350A2 (pt) Derivados de imidazo[1,2-a]piridinila e uso do mesmo no tratamento de doenças
BR112012010518A2 (pt) composto, composição farmacêutica, uso de composto, métodos para estimular um receptor de cb, para tratar uma doença, um distúrbio ou uma condição, para diminuir dano secundário, para a formação de c-amp, processo para a preparação de um composto, e, método para estímulo do crescimento ósseo, massa óssea, reparo ósseo ou prevenção da perda óssea.
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
JOP20190058B1 (ar) مشتقات كرومان، أيزوكرومان وداي هيدرو أيزو بنزوفوران كمُعدلات تفارغية سالبة mGluR2، تركيبات، واستخدامها
Kranz et al. Phosphodiesterase type 4 inhibitor rolipram improves survival of spiral ganglion neurons in vitro
BR112019023109A2 (pt) Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo
BR112022019628A2 (pt) Composto da fórmula (i), enantiômero único, composição farmacêutica, processo para a preparação desta, método para o tratamento de uma condição ou distúrbio mediado pela atividade antagonista do receptor de trpv4 em um animal incluindo um humano, uso de um composto e composto representado pela fórmula (i-d)
BR112022025128A2 (pt) Composições e métodos para tratar doenças e distúrbios usando vesículas extracelulares microbianas de oscillospiraceae
BRPI0809873A2 (pt) "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
García-Hernández et al. Role of fibroblast growth factor 8 in neurite outgrowth from spiral ganglion neurons in vitro
BR112014011336A2 (pt) composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele
BR112019007954A2 (pt) inibidor da aldosterona sintase
Bankole et al. Vitamin D 3 receptor activation rescued corticostriatal neural activity and improved motor function in–D 2 R tardive dyskinesia mice model
US10806739B2 (en) Use of n-desmethylclobazam in the treatment of chronic pain disorders and related methods
Nishimoto et al. Streptozotocin induces neurite outgrowth via PI3K-Akt and glycogen synthase kinase 3β in Neuro2a cells
KR102172375B1 (ko) 프소랄리딘을 포함하는 조성물 및 이의 용도